Normalized net profit of Baht 343 million in Q3’2017-2018. Increase in both the company’s Reported net profit and normalized net profit were mainly from sales growth and lower cost of Food business due to
and administrative expenses for 2Q19 and 1H19 was Baht 124.74 million, and Baht 236.03 million, respectively, which increased from previous period. The increase was mainly due to the expenses of new
& vaccination) was on par with the previous year. This trend also incurred to IPD income with IPD visit number barely changed yoy. while revenue per visit has increased by 10% yoy. The increase of revenue per
in order to increase sales, in the meantime focus on control system and reduce expenses to conform actual incomes which decreased. Performance Analysis Unit : MB For the quarterly Change For the six
Owners of the parent 27.96 8.19% 41.21 34.30% (13.25) (32.15%) Jan – Mar 63 Jan – Mar 62 Increase/(Decrease) DOD BIOTECH PUBLIC COMPANY LIMITED เลขท ี111 หมู่ท ี2 ตําบลท่าจีน อําเภอเมืองสมุทรสาคร จังหวดั
growth momentum and stabilized financial system. The performance of Central Pattana Public Company Limited (“The Company” or “Central Pattana”) in 2019 shows total revenue of THB 38,403 mn, an increase of
to the continuously rising price of cullet which is the key raw material in the production process of amber glass bottles causing the packaging cost to increase considerably. However, the Group
equipment during the period, mostly for business expansion by the Company. Liabilities As at 31 March 2018, the Company and its subsidiaries have liabilities amounted of 29,667.8 million baht. A increase of
generated a slight increase in service revenue (+2.1% YoY and 1.4% QoQ). Our mobile business was flat both YoY and QoQ driven by soft consumer spending offset by our movement to retain market share and build